The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
Cancer Science · 2024
DOI: 10.1111/cas.16198 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Science, 2024. Verfasst von Yutaka Shimazu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Transplantation, Autologous, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara– group) and those administered Dara (Dara+ group), the 1‐year progression‐free survival (PFS) rates were 87.4% and 77.3% and the 1‐year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy, Kyoto University Hospital, Kyoto, Japan.
- Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Division of Clinical Oncology and Hematology, Department of Internal Medicine, the Jikei University School of Medicine, Tokyo, Japan.
- Department of Hematology, University of Toyama, Toyama, Japan.
- Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
ORCID-Profile: Yutaka Shimazu, Junya Kanda, Keisuke Kataoka
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Shimazu, Y., Kanda, J., Suzuki, K., Wada, A., Kikuchi, T., Ikeda, T., Tsukada, N., Miwa, A., Itagaki, M., Kako, S., Nishiwaki, K., Ota, S., Fujiwara, S. I., Kataoka, K., Doki, N., Sawa, M., Hiramoto, N., Nishikawa, A., Imai, T., …, & Kawamura, K. (2024). The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation. Cancer Science. https://doi.org/10.1111/cas.16198
Vancouver
Shimazu Y, Kanda J, Suzuki K, Wada A, Kikuchi T, Ikeda T, et al. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation. Cancer Science. 2024. doi:10.1111/cas.16198
BibTeX
@article{Shimazu2024,
author = {Shimazu, Yutaka and Kanda, Junya and Suzuki, Kazuhito and Wada, Akinori and Kikuchi, Taku and Ikeda, Takashi and Tsukada, Nobuhiro and Miwa, Akiyoshi and Itagaki, Mitsuhiro and Kako, Shinichi and Nishiwaki, Kaichi and Ota, Shuichi and Fujiwara, Shin-Ichiro and Kataoka, Keisuke and Doki, Noriko and Sawa, Masashi and Hiramoto, Nobuhiro and Nishikawa, Akinori and Imai, Toshi and Ichinohe, Tatsuo and Kanda, Yoshinobu and Atsuta, Yoshiko and Kawamura, Koji},
title = {The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16198}
}
EUVIMED